Severe cutaneous adverse reactions in a local hospital setting: a 5‐year retrospective study

Severe cutaneous adverse reactions (SCAR) are rare but important causes of morbidity and mortality. Stevens‐Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) are severe cutaneous drug reactions that can be potentially life threatening. Our study aims to look at the epidemiology of SCAR in the local setting in Singapore and the underlying characteristics of our patients that may influence the drug reaction seen.

[1]  R. Abe.  Cutaneous Adverse Drug Reactions: Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis , 2016 .

[2]  O. Faye,et al.  Treatment of Epidermal Necrolysis with High-Dose Intravenous Immunoglobulins (IVIg) , 2012, Drugs.

[3]  Sang-Heon Cho,et al.  Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans , 2011, Epilepsy Research.

[4]  Martin Schumacher,et al.  Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe , 2011, Orphanet journal of rare diseases.

[5]  H. Y. Lee,et al.  Cutaneous adverse drug reactions in hospitalised patients. , 2010, Singapore medical journal.

[6]  Y. Tay,et al.  Retrospective analysis of drug-induced hypersensitivity syndrome: a study of 27 patients. , 2010, Journal of the American Academy of Dermatology.

[7]  S. Fernando,et al.  Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening , 2010, Canadian Medical Association Journal.

[8]  M. Koh,et al.  Stevens-Johnson syndrome and toxic epidermal necrolysis in Asian children. , 2010, Journal of the American Academy of Dermatology.

[9]  T. Inatomi,et al.  Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset. , 2009, American journal of ophthalmology.

[10]  Z. Ikezawa,et al.  [Analysis of treatments and deceased cases of severe adverse drug reactions--analysis of 46 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis]. , 2009, Arerugi = [Allergy].

[11]  H. Chng,et al.  Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Are Not Just Severe Cutaneous Adverse Reactions , 2008 .

[12]  M. Mockenhaupt,et al.  Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. , 2008, Journal of the American Academy of Dermatology.

[13]  L. Naldi,et al.  Risk factors for acute generalized exanthematous pustulosis (AGEP)—results of a multinational case–control study (EuroSCAR) , 2007, The British journal of dermatology.

[14]  M. Jonkman,et al.  Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. , 2007, Acta dermato-venereologica.

[15]  T. Thirumoorthy,et al.  Serious cutaneous adverse reactions to traditional Chinese medicines. , 2005, Singapore medical journal.

[16]  Yuan-Tsong Chen,et al.  HLA-B genotyping to detect carbamazepine-induced Stevens-Johnson syndrome: implications for personalizing medicine. , 2005, Personalized medicine.

[17]  O. Faye,et al.  Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. , 2005, Drugs.

[18]  J. Roujeau,et al.  Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. , 2003, Archives of dermatology.

[19]  M. Mockenhaupt,et al.  Cutaneous Adverse Drug Reactions , 2002 .

[20]  K. Hui.  Adverse drug reactions in hospitalized patients. , 1998, JAMA.

[21]  R. Stern,et al.  Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. , 1996, The New England journal of medicine.

[22]  L. Naldi,et al.  An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods. , 1995, Journal of clinical epidemiology.

[23]  J. Roujeau,et al.  Intestinal involvement in drug-induced toxic epidermal necrolysis , 1991, The Lancet.

[24]  J. Roujeau,et al.  The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). , 1987, Archives of dermatology.

[25]  K. Arndt,et al.  Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. , 1986, JAMA.